Please login to the form below

Not currently logged in

GSK to supply 85 million doses of pandemic influenza vaccine to EU

The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe


GSK has signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe.

The contract is one of the first signed by HERA since it was launched by the EC in September 2021 with a mission to ‘prevent, detect and rapidly respond to health emergencies’.

Roger Conner, president of Vaccines and Global Health at GSK, said: “I’m delighted that HERA has chosen GSK as a key partner in pandemic flu preparedness… We have all seen the devastating human, economic and social consequences of a pandemic and the important part that vaccines are playing in helping us return to normal life. Through this agreement for 85 million doses, we can help the EU and European countries, as well as other countries and regions, be better prepared for future pandemics.”

Adjupanrix is a vaccine for use in adults to protect against pandemic influenza and, according to the European Medicines Agency (EMA), should only be used once an influenza pandemic has been officially declared by the World Health Organization (WHO) or the EU.

Adjupanrix is a ‘mock-up’ vaccine, a type of vaccine that can be developed to help with the management of a future pandemic. Before an influenza pandemic begins, the strain of flu virus involved is unknown, so the correct vaccine cannot be prepared in advance. Instead, a vaccine can be prepared that contains a strain of flu virus to which very few people are immune. This vaccine can then be tested in advance to see how people react to it, allowing for the prediction of how people will react when the flu strain causing the pandemic is included.

GSK has signed a number of contracts this year under which the company could provide at least 200 million doses of the pandemic influenza vaccine to governments around the world. In February, the company extended its pandemic influenza vaccine stockpile contract with the US government. This was followed by a renewed agreement in June for supply of pandemic influenza vaccines to the World Health Organization (WHO) and a contract with the government of Canada in July for both seasonal and pandemic influenza vaccines.

Article by
Emily Kimber

29th July 2022

From: Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....